That's certainly my guess, too. But you have said in the past the developments in their generic enoxaparin program didn't meet the legal threshold for materiality, so if they did not want to disclose certain aspects of the program, they wouldn't have to. Balanced against that is how much more they've been jabbering about it since Momenta's version got approved. There may be more game theory at work here. How much to reveal? What would be the desired result? Anyhow, this is why I like the question I posed. It might get stonewalled, but worth a try, IMO.
Regards, RockRat
Market Data 
Markets 
AI
